Renata leading the way with science-driven innovation and patient care

I never imagined I would join Renata. My father never pressured me; in fact, he used to say, "I don't think you'll do a great job in business — do something else."

Yet, my academic path naturally drew me to health sciences. I studied biochemical engineering and later clinical pharmacology, preparing me for a life in healthcare. Initially, I planned to work in life science investment banking, but when COVID struck, I returned to Bangladesh. I witnessed the tireless dedication of healthcare professionals — doctors, nurses, factory workers — who risked their lives daily. Their commitment inspired me to contribute to Renata's mission, and I realised I could make a meaningful impact in the sector.

For me, Renata's future rests on two pillars. First, we must remain proudly Bangladeshi while delivering world-class, high-quality medicines to our people. Second, we must harness our talent, research and development, and scientific capacity to serve the global market. We aim to be recognised as a science-led company, focused on research, innovation, and international quality standards. When someone takes a Renata medicine — whether in Bangladesh, Europe, or the US — they should know they are receiving the best possible treatment.

An infographic from The Business Standard details the corporate profile and financial strength of Renata PLC, showing key metrics including turnover, profit after tax, and net asset value per share from FY20 to FY24. | Infograph: TBS

Renata currently produces 83 bioequivalent products. While the concept may sound complex, it is straightforward. When a patient takes a medicine, there is usually an "innovator drug" — the original — and a generic version. Bioequivalence proves that both perform identically in the body, guaranteeing safety, efficacy, and therapeutic effect. This is vital for antibiotics, chemotherapy, and long-term treatments. In Bangladesh, it ensures that people in Comilla, Sylhet, or any other city have access to the same quality medicines available in developed countries.

Innovation is central to our strategy. Internationally, we recently launched a drug in Australia with a unique dosage form developed entirely by Renata. Domestically, we identified a challenge: nurses and clinicians struggled to reconstitute powdered cancer drugs safely. To solve this, we developed ready-to-use injections that remain stable at room temperature, requiring no refrigeration or extra preparation. This innovation saves time, reduces risk, and lowers costs.

We also focus on paediatric oncology. Many drugs are formulated for adults, making safe administration to children extremely difficult. We developed titratable versions that can be adjusted for individual weights and dosages. We conducted clinical trials, proved efficacy and safety, and patented the formulations under Renata's name. While we are not yet full-fledged innovators, these steps pave the way for Renata to become one.

I often follow global pharmaceutical developments and dream of a future where people ask: "What new drug has Renata come out with?" This vision motivates me every day. What excites me most is that these innovations are driven by young talent in Bangladesh. Providing them with platforms and opportunities is critical; otherwise, they may move abroad. Empowered, they will take the industry further than we ever imagined.

I am optimistic about Bangladesh's pharmaceutical industry. With dedication, ethical practices, and focus on research and development, I believe we are moving in the right direction. Renata is well-positioned to be recognised as a science-led, globally competitive company. Our mission remains clear: to deliver world-class medicines to our people while contributing meaningfully to global healthcare. This is both our responsibility and our ambition, and I am proud to be part of it.